MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Conivaptan hydrochloride

CAS No. : 168626-94-6

MCE 站：Conivaptan hydrochloride

产品活性：Conivaptan hydrochloride 是一种非肽段类的 vasopressin receptor 拮抗剂，能够抑制大鼠肝脏的 V1A 受体 和 肾脏的 V2 受体，K_i 值分别为 0.48 和 3.04 nM。

研究领域：GPCR/G Protein

作用靶点：Vasopressin Receptor

In Vivo: Conivaptan (0.03, 0.1 and 0.3 mg/kg, i.v.) dose-dependently increases urine volume and reduces urine osmolality in both myocardial infarction and sham-operated rats. Conivaptan (0.3 mg/kg i.v.) significantly reduces right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Conivaptan (0.3 mg/kg i.v.) significantly increases dP/dt(max)/left ventricular pressure in myocardial infarction rats. Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure. Conivaptan (0.01 to 0.1 mg/kg, i.v.) exerts a dose-dependent diuretic effect in dogs without an increase in the urinary excretion of electrolytes, inhibits the pressor effect of exogenous vasopressin in a dose-dependent manner (0.003 to 0.1 mg/kg i.v.) and, at the highest dose (0.1 mg/kg i.v.), almost completely blocks vasoconstriction caused by exogenous vasopressin. Conivaptan (0.1 mg/kg, i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Argipressin  |  Atosiban  |  Tolvaptan  |  Felypressin  |  Lixivaptan  |  Terlipressin acetate  |  Mozavaptan  |  Fuscoside  |  SRX246  |  Big Endothelin-1 (1-38), human  |  D[LEU4,LYS8]-VP TFA  |  L-371,257  |  SKF 100398  |  WAY-151932  |  Antagonist G  |  Big Endothelin-1 (1-39), porcine  |  d[Cha4]-AVP

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。